International Stem Cell Corporation (ISCO)
- Previous Close
0.0712 - Open
0.0612 - Bid --
- Ask --
- Day's Range
0.0612 - 0.0684 - 52 Week Range
0.0500 - 0.1700 - Volume
1,566 - Avg. Volume
1,264 - Market Cap (intraday)
520,285 - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
www.internationalstemcell.comRelated News
Performance Overview: ISCO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ISCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ISCO
Valuation Measures
Market Cap
520.28k
Enterprise Value
3.12M
Trailing P/E
4.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.07
Price/Book (mrq)
--
Enterprise Value/Revenue
0.40
Enterprise Value/EBITDA
15.42
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.68%
Return on Assets (ttm)
-7.87%
Return on Equity (ttm)
--
Revenue (ttm)
7.79M
Net Income Avi to Common (ttm)
-131k
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.59M
Total Debt/Equity (mrq)
3,697.34%
Levered Free Cash Flow (ttm)
380.75k
Company Insights: ISCO
ISCO does not have Company Insights